论文部分内容阅读
目的观察阿奇霉素治疗无危险因素社区获得性肺炎(CAP)的临床疗效和安全性。方法将98例CAP患者随机分成2组:对照组(n=48例)用头孢曲松钠2.0 g加入100 ml 0.9%氯化钠注射液中静脉滴注,2次/d,连续7~10 d;治疗组(n=50例)阿奇霉素500 mg加入5%葡萄糖或0.9%氯化钠注射液250~500 ml中静脉滴注,1次/d,5~7 d。观察疗效及不良反应。结果治疗组有效45例(90.0%),对照组有效38例(79.2%),治疗组有效率略高于对照组,但差异无统计学意义(P>0.05)。不良反应发生率治疗组12.0%,对照组为10.4%。结论阿奇霉素治疗无危险因素CAP患者疗效好,且较安全。
Objective To observe the clinical efficacy and safety of azithromycin in the treatment of community-acquired pneumonia (CAP), a non-risk factor. Methods Ninety-eight patients with CAP were randomly divided into two groups: the control group (n = 48) with ceftriaxone sodium 2.0 g added 100 ml 0.9% sodium chloride injection intravenously, 2 times / d, continuous 7 to 10 d; treatment group (n = 50 cases) azithromycin 500 mg with 5% glucose or 0.9% sodium chloride injection 250 ~ 500 ml intravenous infusion, 1 / d, 5 ~ 7 d. Observation of efficacy and adverse reactions. Results 45 cases (90.0%) were effective in the treatment group and 38 cases (79.2%) in the control group. The effective rate of the treatment group was slightly higher than that of the control group, but the difference was not statistically significant (P> 0.05). The incidence of adverse reactions was 12.0% in the treatment group and 10.4% in the control group. Conclusions Azithromycin has a good effect and is safe in patients with CAP without risk factors.